Differences in radiosensitivity between three HER2 overexpressing cell lines
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
HER2 is a potential target for radionuclide therapy, especially when HER2 overexpressing breast cancer cells are resistant to Herceptin® treatment. Therefore, it is of interest to analyse whether HER2 overexpressing tumour cells have different inherent radiosensitivity.
The radiosensitivity of three often used HER2 overexpressing cell lines, SKOV-3, SKBR-3 and BT-474, was analysed. The cells were exposed to conventional photon irradiation, low linear energy transfer (LET), to characterise their inherent radiosensitivity. The analysis was made with clonogenic survival and growth extrapolation assays. The cells were also exposed to alpha particles, high LET, from 211At decays using the HER2-binding affibody molecule 211At-(ZHER2:4)2 as targeting agent. Assays for studies of internalisation of the affibody molecule were applied.
SKOV-3 cells were most radioresistant, SKBR-3 cells were intermediate and BT-474 cells were most sensitive as measured with the clonogenic and growth extrapolation assays after photon irradiation. The HER2 dependent cellular uptake of 211At was qualitatively similar for all three cell lines. However, the sensitivity to the alpha particles from 211At differed; SKOV-3 was most resistant, SKBR-3 intermediate and BT-474 most sensitive. These differences were unexpected because it is assumed that all types of cells should have similar sensitivity to high-LET radiation. The sensitivity to alpha particle exposure correlated with internalisation of the affibody molecule and with size of the cell nucleus.
There can be differences in radiosensitivity, which, if they also exist between patient breast cancer cells, are important to consider for both conventional radiotherapy and for HER2-targeted radionuclide therapy.
- Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23(9):1147–57. CrossRef
- DeNardo SJ, DeNardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 2006;66(2 Suppl):S89–95.
- Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006;50(4):248–64.
- O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36(10):1902–9.
- Carlsson J, Forssell AE, Hiet-ala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003;66:107–17. CrossRef
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82. CrossRef
- Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087–91.
- Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036–43. CrossRef
- Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344–8.
- Steel GG. Basic clinical radiobiology. London: Hodder Education; 2002.
- Hall EJ, Giaccia AJ. Radiobiology for the radiologist. Philadelphia: Lippincott Williams & Wilkins; 2006.
- Deacon J, Peckham MJ, Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 1984;2:317–23. CrossRef
- Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 1996;34(1):251–66.
- Karlsson KH, Stenerlow B. Focus formation of DNA repair proteins in normal and repair-deficient cells irradiated with high-LET ions. Radiat Res 2004;161:517–27. CrossRef
- Johansson L, Nilsson K, Carlsson J, Larsson B, Jakobsson P. Radiation effects on cultured human lymphoid cells. Analysis using the growth extrapolation method. Acta Radiol Oncol 1981;20:51–9. CrossRef
- Persson MI, Gedda L, Jensen HJ, Lundqvist H, Malmstrom PU, Tolmachev V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep 2006;15(3):673–80.
- Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng DeS Selection (PEDS) 2004;17(5):455–62. CrossRef
- Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson F, Ståhl S, et al. In vitro characterization of a bivalent anti-HER2 affibody with potential for radionuclide based diagnostics. Cancer Biother Radiopharm 2005;20(3):239–48. CrossRef
- Steffen AC, Orlova A, Wikman M, Nilsson F, Ståhl S, Adams GP, et al. Affibody mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006;33(6):631–8. CrossRef
- Orlova A, Magnusson M, Eriksson T, Nilsson M, Larsson B, Höiden-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER-2 binding affibody molecule. Cancer Res 2006;66(8):4339–433. CrossRef
- Tolmachev V, Orlova A, Pehrson R, Galli J, Baastorp B, Andersson K, et al. Radionuclide therapy of HER2-positive micro-xenografts using a 177-Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007;67(6):2773–82. CrossRef
- Hartman T. Tumour targeting with stable and radioactive nuclides: dosimetric aspects at the cellular level. Doctoral thesis, Uppsala University. Uppsala: Acta Universitatis Upsaliensis; 1999.
- Palm S, Humm JL, Rundqvist R, Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys 2004;31:218–25. CrossRef
- Palm S. In vitro effects and microdosimetry of astatine-211 for tumour therapy. Doctoral thesis, University of Göteborg, Sahlgrenska University Hospital (ISBN 91-628-3841-5); 1999.
- Nordberg E, Friedman M, Göstring L, Adams GP, Brismar H, Nilsson FY, et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 2007;34(6):609–18. CrossRef
- Dikomey E, Brammer I. Relationship between cellular radiosensitivity and non-repaired double-strand breaks studied for different growth states, dose-rates and plating conditions in a normal human fibroblast line. Int J Radiat Biol 2000;76(6):773–81. CrossRef
- Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196–9.
- Carlsson J, Hakansson E, Eriksson V, Grawe J, Wester K, Grusell E, et al. Early effects of low dose-rate radiation on cultured tumor cells. Cancer Biother Radiopharm 2003b;18:663–70. CrossRef
- Lennartsson J, Carlsson J, Stenerlöw B. Targeting the epidermal growth factor receptor family in radionuclide therapy of tumors–signal transduction and DNA repair. Lett Drug Des Discov 2006;3:357–68. CrossRef
- Petru E, Sevin BU, Gottlieb C. Radiosensitivity patterns of four human ovarian cancer cell lines in vitro. Gynecol Oncol 1997;64:490–2. CrossRef
- Steren A, Sevin BU, Perras J, Angioli R, Nguyen H, Guerra L, et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 1993;48(2):252–8. CrossRef
- Joiner MC, Marples B, Lambin P, Short SC, Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 2001;49(2):379–89. CrossRef
- Murray D, McEwan AJ. Radiobiology of systemic radiation therapy. Cancer Biother Radiopharm 2007;22(1):1–23. CrossRef
- Chapman JD. Single-hit mechanism of tumour cell killing by radiation. Int J Radiat Biol 2003;79:71–81. CrossRef
- Prise KM, Folkard M, Michael BD. A review of the bystander effect and its implications for low-dose exposure. Radiat Prot Dosim 2003;104(4):347–55.
- Stenerlow B, Pettersson O, Essand M, Blomquist E, Carlsson J. Irregular variations in radiation sensitivity when the linear energy transfer is increased. Radiother Oncol 1995;36(2):133–42. CrossRef
- Ekerljung L, Steffen AC, Carlsson J, Lennartsson J. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 2006;27(4):201–10. CrossRef
- Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 2004;48:289–96.
- Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22(6):701–6. CrossRef
- Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006;47(5):793–6.
- Differences in radiosensitivity between three HER2 overexpressing cell lines
European Journal of Nuclear Medicine and Molecular Imaging
Volume 35, Issue 6 , pp 1179-1191
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- High LET
- Nuclear medicine
- Radiation effects
- Tumour cells
- Industry Sectors
- Author Affiliations
- 1. Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, 751 85, Sweden
- 2. Affibody AB, Bromma, 161 02, Sweden
- 3. Department of Radiation Physics, Sahlgrenska Academy at Göteborg University, 413 45, Göteborg, Sweden
- 4. Biomedical Radiation Sciences, Rudbeck Laboratory, 751 85, Uppsala, Sweden